Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more

Recent & Breaking News (NDAQ:NKTR)

NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain

PR Newswire March 20, 2017

Technical Reports on Biotech Stocks -- Nektar Therapeutics, Seattle Genetics, Dynavax Technologies, and BioMarin Pharma

PR Newswire March 13, 2017

Nektar to Webcast Presentation at Cowen and Company's 37th Annual Health Care Conference in Boston

PR Newswire March 2, 2017

25 Biggest Mid-Day Gainers For Thursday

Benzinga.com  March 2, 2017

Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting

PR Newswire March 1, 2017

Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results

PR Newswire March 1, 2017

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2016 on Wednesday, March 1, 2017, After Close of U.S.-Based Financial Markets

PR Newswire February 22, 2017

Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium

PR Newswire February 18, 2017

Benzinga's Option Alert Recap From January 23

Benzinga.com  January 23, 2017

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

PR Newswire January 5, 2017

Why The Last Week Of 2016 Could Be Big For Biotech Catalysts

Benzinga.com  December 27, 2016

Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings

PR Newswire Europe Non Regulatory December 27, 2016

Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings

PR Newswire December 27, 2016

Watch These 7 Huge Put Purchases In Tuesday Trade

Benzinga.com  December 6, 2016

Biotech Stocks on Investors' Radar -- Vertex Pharma, Nektar Therapeutics, CTI BioPharma, and Sage Therapeutics

PR Newswire November 22, 2016

Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London

PR Newswire November 14, 2016

Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

PR Newswire November 9, 2016

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016

PR Newswire November 3, 2016

Nektar to Hold Investor & Analyst Event at 2016 Society for Immunotherapy of Cancer Annual Meeting

PR Newswire October 28, 2016

Nektar Therapeutics Announces Upcoming Presentations at the 2016 Society for Immunotherapy of Cancer Annual Meeting

PR Newswire October 28, 2016